Edition:
United States

Arrowhead Pharmaceuticals Inc (ARWR.OQ)

ARWR.OQ on NASDAQ Stock Exchange Global Select Market

3.14USD
15 Dec 2017
Change (% chg)

$-0.01 (-0.32%)
Prev Close
$3.15
Open
$3.19
Day's High
$3.20
Day's Low
$3.09
Volume
623,691
Avg. Vol
223,684
52-wk High
$4.53
52-wk Low
$1.20

Chart for

About

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of... (more)

Overall

Beta: 1.81
Market Cap(Mil.): $234.78
Shares Outstanding(Mil.): 74.77
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Silence Therapeutics Says Sold Further Part Of Holding In Arrowhead Pharmaceuticals Inc

* HAS SOLD A FURTHER PART OF ITS HOLDING OF COMMON SHARES IN ARROWHEAD PHARMACEUTICALS INC.

Dec 11 2017

BRIEF-Silence Therapeutics Says Sold Part Of Holding Of Common Shares In Arrowhead Pharmaceuticals

* THAT IT HAS SOLD PART OF ITS HOLDING OF COMMON SHARES IN ARROWHEAD PHARMACEUTICALS INC​

Dec 04 2017

BRIEF-Silence Therapeutics Plc Reports 6.4 Pct Stake In Arrowhead Pharmaceuticals As Of Nov 29

* SILENCE THERAPEUTICS PLC REPORTS 6.4 PERCENT STAKE IN ARROWHEAD PHARMACEUTICALS INC AS OF NOVEMBER 29 - SEC FILING

Dec 01 2017

BRIEF-Arrowhead Qtrly loss per share $0.07

* Qtrly revenue $9.3 million versus $39,583 Source text for Eikon: Further company coverage:

Aug 03 2017

Earnings vs. Estimates